Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma. A phase II study of the gynecologic oncology group

H. B. Muss, G. P. Sutton, B. Bundy, K. D. Hatch

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Twenty-six evaluable patients with advanced or recurrent squamous cell carcinoma of the uterine cervix were treated with mitoxantrone at a dosage of 12 mg/m2 every 3 weeks. Twenty-five of 26 patients had had prior irradiation and 24 prior chemotherapy. There were two partial responses, one in a patient with pelvic recurrence and another in a patient with a right upper quadrant mass. Progression-free intervals for these two patients were 5.1 and 4.6 months, respectively. Toxicity was moderate and consisted mainly of leukopenia. No septic or bleeding complications were observed. Mitoxantrone is minimally active in patients with advanced cervical cancer who have been previously treated.

Original languageEnglish (US)
Pages (from-to)312-315
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume8
Issue number4
DOIs
StatePublished - Jan 1 1985
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma. A phase II study of the gynecologic oncology group'. Together they form a unique fingerprint.

  • Cite this